Discontinue use in patients w/ clinically significant hypersensitivity, SJS. Long-term effects in AML. Not to be used in MDS, chronic myelogenous leukemia & secondary AML. De novo
AML patients <55 yr; recent history of pulmonary infiltrates or pneumonia; glomerulonephritis; MDS & AML in breast & lung cancer patients; sickle cell trait or disease; aortitis. Immunogenicity. Monitor for preliminary signs of acute resp distress syndrome; urinalysis. Closely monitor patients who develop capillary leak syndrome & spleen size. Regularly monitor platelet count & hematocrit & perform WBC count. Mobilisation of blood progenitor cells in patients or healthy donors. Transient +ve bone-imaging findings. May cause allergic reactions due to latex. High-dose use. Dietary intake of sorbitol/fructose. Not recommended in women of childbearing potential & during pregnancy. Lactation. Childn.